Drugs / VADACABTAGENE LERALEUCEL
VADACABTAGENE LERALEUCEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02973191 | Dec 2016 → Jun 2019 | precursor lymphoblastic lymphoma/leukemia | Celgene Corporation | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT02535364 | Aug 2015 → Apr 2017 | acute lymphoblastic leukemia | Juno Therapeutics, a Subsidiary of Celgene | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VADACABTAGENE LERALEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990020 ↗ |
| Known as | JCAR015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02973191 ↗ |
| Known as | Vadacabtagen leraleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990020 ↗ |
| Action | Deplete | “help the body's immune system eliminate leukemia cells” NCT02535364 ↗ |
| Modality | Cell therapy | “an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR)” NCT02535364 ↗ |
| Route | Intravenous | “JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.” NCT02535364 ↗ |